We examined the response of patients who received intravenous infusions of autologous leukemia cells transduced ex vivo to express a recombinant CDI 54 (termed """"""""Ad-CD154 gene-Rx""""""""). We found such treatment could induce p53-dependent genes encoding pro-apoptotic proteins in non-transduced """"""""bystander"""""""" CLL cells that lacked functional p53 via c-abl-kinase activafion of TAp7S. Activation of TAp7S could sensitize such drug-resistant CLL cells to the cytotoxic effects of drugs that ordinarily require functional p53. Ad-CD154 gene Rx also could induce auto antibodies to ROR1, which found absent on normal adult tissues, but expressed on CLL cells of virtually all cases, where it plays an apparent role in pathogenesis. We hypothesize that treatment of CLL patients with lenalidomide might mimic these effects of Ad-CDI 54 gene Rx. We also propose that ROR1could serve as an excellent target for development of novel therapies. Finally, ROR1 is one of several receptors for factors engaged in the cross talk between CLL cells and its microenvironment. CLL cells simulated by nurse like cells (NLC) found in the CLL microenvironment are induced to elaborate chemokines (CCLS and CCL4) that can recruit T cells and NLC-precursor cells to the microenvironment. Preliminary data suggest that the serum levels of CCL3/CCL4 might serve as surrogate markers of disease activity and possibly of early response to novel therapies intended to induce immune activation or cause disruption of the CLL microenvironment that are being investigated by the CRC. To take advantage of these observations we have the following specific aims: 1. Evaluate whether lenalidomide can induce anti-ROR1 auto antibodies and mimic the capacity of Ad-CDI 54 Gene Rx to enhance sensitivity of drug-resistant CLL cells to chemotherapy. Determine whether such effects are noted primarily in patients who are most likely to respond favorably to lenalidomide;2. Evaluate expression levels of CCLS and CCL4 in relation to disease progression or response to treatment strategies intended to induce immune activation or disrupt the CLL microenvironment;3. Evaluate strategies to target RORI with RORI vaccines, anti-ROR1 mAbs, T cells bearing ROR1-specific chimeric antigen receptors, or drug-laden liposomes that target ROR1.

Public Health Relevance

The studies in this project could define novel and effective therapies for patients with drug-refractory CLL or CLL in general. These studies also might validate surrogate markers of aggressive disease and/or response to therapy with agents intended to induce immune activation or disruption of the CLL microenvironment that are being investigated by the CRC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA081534-14
Application #
8733427
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
14
Fiscal Year
2014
Total Cost
$239,121
Indirect Cost
$35,000
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Kashyap, Manoj K; Kumar, Deepak; Jones, Harrison et al. (2016) Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget 7:2809-22
Lamothe, Betty; Wierda, William G; Keating, Michael J et al. (2016) Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clin Cancer Res 22:4712-26
Oakes, Christopher C; Seifert, Marc; Assenov, Yassen et al. (2016) DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet 48:253-64
Balatti, Veronica; Acunzo, Mario; Pekarky, Yuri et al. (2016) Novel mechanisms of regulation of miRNAs in CLL. Trends Cancer 2:134-143
Lampson, Benjamin L; Kasar, Siddha N; Matos, Tiago R et al. (2016) Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128:195-203
Salzer, Elisabeth; Cagdas, Deniz; Hons, Miroslav et al. (2016) RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. Nat Immunol 17:1352-1360
Dhar, Sachin; La Clair, James J; León, Brian et al. (2016) A Carbohydrate-Derived Splice Modulator. J Am Chem Soc 138:5063-8
Hawkins, Edwin D; Duarte, Delfim; Akinduro, Olufolake et al. (2016) T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature 538:518-522
Sarkar, Aloke; Balakrishnan, Kumudha; Chen, Jefferson et al. (2016) Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget 7:3461-76
Thompson, Philip A; O'Brien, Susan M; Xiao, Lianchun et al. (2016) β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122:565-73

Showing the most recent 10 out of 440 publications